Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 72-year-old man comes to the clinic for a follow-up visit 4 weeks after being diagnosed with symptomatic atrial fibrillation. His medical history includes a mechanical aortic valve replacement performed 5 years ago, essential hypertension, and hyperlipidemia. His daily medications are warfarin, simvastatin, and lisinopril. His international normalized ratio (INR) has been stable between 2.0 and 3.0 for the past two years. Two weeks ago, his cardiologist started him on oral amiodarone for rhythm control. The patient currently feels well and reports no palpitations, dyspnea, cough, muscle pain, or unusual bruising. Vital signs are within normal limits. To appropriately evaluate and monitor this patient's pharmacotherapy, which of the following laboratory parameters or diagnostic tests are indicated at this time and periodically during maintenance therapy? Select all that apply.

  1. Serum thyroid-stimulating hormone (TSH)Cevap
  2. International normalized ratio (INR)Cevap
  3. Hepatic aminotransferases (AST and ALT)Cevap
  4. D
    Activated partial thromboplastin time (aPTT)
  5. E
    Scheduled pulmonary function tests (PFTs)
  6. F
    Routine serum creatine kinase (CK)

Cevap

The indicated parameters for ongoing monitoring are serum thyroid-stimulating hormone (TSH), international normalized ratio (INR), and hepatic aminotransferases (AST and ALT).
Amiodarone is a class III antiarrhythmic with a complex toxicity profile and significant drug-drug interactions. Because it contains iodine and affects thyroid hormone metabolism, TSH must be monitored at baseline and every 6 months. It can also cause insidious hepatotoxicity, necessitating AST and ALT checks at baseline and every 6 months. Furthermore, amiodarone is a potent inhibitor of multiple cytochrome P450 enzymes, particularly CYP2C9. Warfarin is metabolized primarily by CYP2C9; therefore, adding amiodarone significantly increases serum warfarin concentrations, elevating the risk of bleeding. The INR must be monitored closely upon amiodarone initiation, and an empiric warfarin dose reduction of 25% to 50% is standard practice.

Adım Adım Çözüm

1
Identify the primary medication being initiated and its inherent toxicity profile.
The patient was recently started on amiodarone, a medication with known thyroid, hepatic, and pulmonary toxicities.
Amiodarone requires strict baseline and periodic surveillance to detect asymptomatic organ toxicity.
2
Determine the recommended routine monitoring intervals for amiodarone.
Guidelines recommend checking TSH and AST/ALT at baseline and every 6 months. A chest X-ray is required annually, but routine PFTs are not required unless symptoms develop.
Periodic screening prevents progression of asymptomatic end-organ damage caused by amiodarone.
3
Evaluate potential pharmacokinetic interactions between the new medication and the patient's existing regimen (warfarin, simvastatin, lisinopril).
Amiodarone inhibits CYP2C9 (increasing warfarin levels) and CYP3A4 (increasing simvastatin levels).
Recognizing drug-drug interactions is critical for anticipating adverse events like bleeding or myopathy.
4
Determine the appropriate monitoring strategy for the identified drug interactions.
The interaction with warfarin requires close, frequent monitoring of the INR (and typically a dose reduction of warfarin). The interaction with simvastatin requires a simvastatin dose reduction, but routine CK monitoring is not indicated unless the patient is symptomatic.
Lab monitoring must align with evidence-based guidelines; over-ordering confirmatory tests for asymptomatic patients leads to unnecessary interventions.

Anahtar Kavram

Patients initiated on amiodarone require periodic monitoring of thyroid and liver function, as well as vigilant monitoring of the INR if co-administered with warfarin due to potent CYP2C9 inhibition.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru